Bharat Biotech And Serum Institute Set To Manufacture Doses For Intranasal COVID-19 Vaccines
Bharat Biotech and Serum Institute of India are going to manufacture two intranasal COVID-19 vaccines. While Bharat Biotech is producing one billion doses for Washington University School of Medicine's adenoviral intranasal vaccine candidate, Serum Institute of India has startedmanufacturing US-based Codagenix's CDX-005, another intranasal vaccine.
Both the Indian pharmaceuticals have two vaccines under trials in the country, already. Covaxin, Bharat Biotech's indigenious COVID-19 vaccine has completed Phase I trials. Serum Institute of India is conducting Phase III trials for Astrazeneca's Oxford trials in India.
Do you always want to share the authentic news with your friends?
Subscribed Successfully...
Enter Valid Email Id
Next Story